Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1984 1
1990 1
1995 2
1998 1
1999 1
2004 2
2005 1
2007 2
2010 3
2011 2
2012 2
2013 3
2014 4
2015 5
2016 3
2017 7
2018 7
2019 4
2020 5
2021 15
2022 13
2023 12
2024 12
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Olfaction: a review.
Jones N, Rog D. Jones N, et al. Among authors: rog d. J Laryngol Otol. 1998 Jan;112(1):11-24. doi: 10.1017/s0022215100139829. J Laryngol Otol. 1998. PMID: 9538440 Review. No abstract available.
Fingolimod-associated macular oedema.
Jasani KM, Sharaf N, Rog D, Aslam T. Jasani KM, et al. Among authors: rog d. BMJ Case Rep. 2017 Jun 15;2017:bcr2016218912. doi: 10.1136/bcr-2016-218912. BMJ Case Rep. 2017. PMID: 28619738 Free PMC article. No abstract available.
Assisted reproduction technology in multiple sclerosis.
Mullan G, Hughes S, Rog D, Brex P, Dobson R. Mullan G, et al. Among authors: rog d. Pract Neurol. 2025 Jul 14;25(4):300-302. doi: 10.1136/pn-2024-004459. Pract Neurol. 2025. PMID: 39832922 No abstract available.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: rog d. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article.
Addressing Homelessness Among Older Adults: Final Report [Internet].
Henderson KA, Manian N, Rog DJ, Robison E, Jorge E, Al-Abdulmunem M; Westat. Henderson KA, et al. Among authors: rog dj. Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2023 Oct 26. Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2023 Oct 26. PMID: 39250572 Free Books & Documents. Review.
Permanent supportive housing: assessing the evidence.
Rog DJ, Marshall T, Dougherty RH, George P, Daniels AS, Ghose SS, Delphin-Rittmon ME. Rog DJ, et al. Psychiatr Serv. 2014 Mar 1;65(3):287-94. doi: 10.1176/appi.ps.201300261. Psychiatr Serv. 2014. PMID: 24343350 Review.
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Chataway J, Williams T, Blackstone J, John N, Braisher M, De Angelis F, Bianchi A, Calvi A, Doshi A, Apap Mangion S, Wade C, Bordea E, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson NP, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri SK, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Tebbs S, Hawton A, Hunter R, Giovannoni G, Ciccarelli O, Beveridge J, Nixon S, Thompson AJ, Greenwood J, Pearson OR, Evangelou N, Sharrack B, Galea I, Gray E, Pavitt S, Chandran S, Ford HL, Frost C, Nicholas JM; MS-STAT2 Investigators. Chataway J, et al. Among authors: rog d. Lancet. 2025 Oct 11;406(10512):1611-1624. doi: 10.1016/S0140-6736(25)01039-6. Epub 2025 Oct 1. Lancet. 2025. PMID: 41045938 Free article. Clinical Trial.
97 results